Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report

Table 1

Changes in rheumatoid arthritis disease activity indexes and levels of serological markers after the introduction of baricitinib.

Week	0	4	24	52
CDAI	57.2	4.0	6.0	6.5
SDAI	68.8	5.1	6.0	6.5
DAS28-CRP	7.61	3.00	2.29	2.34
CRP (mg/dL)	11.6	1.1	0.0	0.0
ESR (mm/h)	104	54	20	14
RF (IU/mL)	65	57	40	9
MMP-3 (ng/mL)	715.3	253.7	68.7	18.1
SAA (μg/mL)	789.0	89.7	7.4	5.0
ACPA (IU/mL)	3472	—	—	329.1
HAQ	2.000	0.500	1.000	1.375

CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; DAS28-CRP: disease activity score 28 based on C-reactive protein (CRP) level; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; MMP-3: matrix metalloproteinase-3; SAA: serum amyloid A; ACPA: anti-citrullinated protein antibody; HAQ: Health Assessment Questionnaire.